Stellantis Shifts to Tesla’s EV Charging Standardby Lilu Anderson 12.02.2024Stellantis has announced it will adopt Tesla's North American Charging Standard, solidifying Tesla's dominance in the EV charging market. This ...
Greenidge Nets $6M Boost: A Turnaround Tale?by John Darbie 12.02.2024Greenidge Generation Holdings secures $6 million investment from Armistice Capital to drive growth and expand its power centers and bitcoin ...
S&P 500 Eyes 5300 Peak Amid Surging Growthby Mark Eisenberg 12.02.2024UBS predicts S&P 500 will reach 5,300, exceeding 7% growth rate. Positive earnings and economic outlook contribute to optimistic market ...
Liberia & Guinea’s $5B Leap with Liberty Corridor: A Game-Changerby John Darbie 12.02.2024Mining billionaire Robert Friedland's company, HPX, is partnering with Liberia's government and Guma Africa Group for a $5 billion infrastructure ...
BofA Initiates PSBD Coverage: Neutral With 12% Upsideby Mark Eisenberg 12.02.2024BofA Securities initiates coverage on Palmer Square Capital BDC with a Neutral rating. Market valuation reflects risks and rewards, potential ...
Rail Vision’s Revolutionary AI Enhancing Railway Safetyby Lilu Anderson 12.02.2024Rail Vision has unveiled its next-generation AI-based computer, aimed at enhancing railway safety and preventing accidents by detecting potential hazards. ...
JPMorgan Bullish on Palmer Square Capital BDCby Mark Eisenberg 12.02.2024JPMorgan gives an optimistic outlook for Palmer Square Capital BDC, assigning it an Overweight rating and $17.00 price target. The ...
CNX’s $400M Move: Strategic Shift or Risky?by Mark Eisenberg 12.02.2024CNX Resources raises $400 million in senior notes offering and launches tender offer, positioning the company for future growth in ...
Novo Nordisk’s Sales Surge: Eyeing $7B Annual Investmentby Mark Eisenberg 12.02.2024Novo Nordisk sees massive sales jump and expects further growth in 2024, driven by the demand for its diabetes and ...
Bristol Myers Bags RayzeBio in $4.1B Cancer Fight Pactby Mark Eisenberg 12.02.2024Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...